Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-operative (at Baseline Assessments Visit) hemoglobin (Hgb) ≥9.0 g/dL (deciliter)~* Pre-operative (at Baseline Assessments Visit) fibrinogen level ≥150 mg/dL (functional method).~* Required one of the following procedures:~  1. An elective (non-emergency), open (non-laparoscopic; non- endovascular) surgical procedure involving a native artery-graft end-to-side proximal anastomosis utilizing coated or uncoated polytetrafluoroethylene (PTFE) graft (IG1202-A).~ 2. An elective (non-emergency), open (non-laparoscopic) hepatic resection (anatomic and non-anatomic resections of at least one anatomical hepatic segment or equivalent tissue volume) (IG-1202-B).~ 3. An elective (non-emergency), open (non-laparoscopic), surgical procedure involving soft (non-parenchymous) tissue (IG1202-C).~ 4. An elective (non-emergency), spinal surgical procedure in which the epidural venous plexus was exposed (IG1202-D).~* A target bleeding site (TBS) was identified according to the Investigator's judgment, and the TBS had mild or moderate bleeding according to the Investigator's judgment.~Exclusion Criteria:~* Required surgical procedure due to trauma (except for spinal surgery).~* Infection in the anatomic surgical area.~* History of severe (e.g. anaphylactic) reactions to blood or to any blood-derived (human or animal) product.~* Previous known sensitivity to any Topical Thrombin (Human) Grifols component, any Bovine Thrombin JMI component, porcine collagen, and heparin or protamine (vascular surgery only) component.~* Received an organ transplant.~* Underwent another concurrent major surgical intervention beyond the liver (applied to hepatic surgery \[IG1202-B\] only; concurrent interventions on the pancreas, gall bladder, bile duct, or intestines were allowed).~* Underwent a re-operative procedure, which was defined as a second, or successive, surgical procedure on the same anatomic location.~* Underwent other vascular procedures during the same surgical session (applied to vascular surgery \[IG1202-A\] only; stenting and/or endarterectomy of the same artery were allowed).~* Underwent a therapeutic surgical procedure within 30 days from screening (diagnostic procedures were allowed).~* Previously included in this trial (i.e. each subject could only be enrolled once in this study).~* TBS could not be identified according to the investigator's judgment.~* TBS had a severe bleeding according to the Investigator's judgment.~* Occurrence of major intra-operative complications that required resuscitation or deviation from the planned surgical procedure.~* Application of any topical haemostatic material on the resection surface of the liver prior to application of the study treatment (applied to hepatic surgery \[IG1202-B\] only).~* Radiofrequency precoagulation of the liver resection surface, except focal use of radiofrequency as primary haemostatic treatment (applied to hepatic surgery \[IG1202-B\] only).~* Intra-operative change in planned surgical procedure which resulted in subject no longer meeting preoperative inclusion and/or exclusion criteria.~* Application of any topical haemostatic material on the cut soft tissue surface prior to application of the study treatment (applied to soft tissue surgery \[IG1202-C\] only).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IG1202-A (Vascular) (Type: EXPERIMENTAL): None
- IG1202-B (Hepatic) (Type: EXPERIMENTAL): None
- IG1202-C (Soft Tissue) (Type: EXPERIMENTAL): None
- IG1202-D (Spinal) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).